Mogensen Jens, Hey Thomas, Lambrecht Sascha
Department of Cardiology, Odense University Hospital, Odense, Denmark.
Department of Cardiology, Odense University Hospital, Odense, Denmark.
Can J Cardiol. 2015 Nov;31(11):1377-85. doi: 10.1016/j.cjca.2015.06.015. Epub 2015 Jun 23.
Genetic investigations have established that mutations in proteins of the contractile unit of the myocardium, known as the sarcomere, may be associated with hypertrophic cardiomyopathy (HCM), restrictive cardiomyopathy (RCM), and dilated cardiomyopathy (DCM). It has become clinical practice to offer genetic testing in affected individuals to identify causative mutations, which provides the basis for presymptomatic testing of relatives who are at risk of disease development. This ensures adequate clinical follow-up of mutation carriers, whereas noncarriers can be discharged. However, before genetic testing can be used for individual risk assessment and prediction of prognosis, it is important to investigate if there is a relation between the clinical disease expression (phenotype) of the condition and mutations in specific disease genes (genotype).
We reviewed the literature in relation to phenotypic features reported to be associated with mutations in cardiac troponin I (cTnI; TNNI3), which is a recognized sarcomeric disease gene in all 3 cardiomyopathies.
The results of this review did not identify specific genotype-phenotype relations in HCM or DCM, and cTnI appeared to be the most frequent disease gene in RCM.
To further explore if there is a genotype-phenotype relation, long-term follow-up studies are needed. It is essential to investigate the natural history of the condition among affected individuals and to provide clinical follow-up on disease development among healthy mutation carriers. Such information is required to provide evidence-based counselling for affected families and to elucidate if knowledge about specific genotypes can be used in future risk prediction models.
遗传学研究已证实,心肌收缩单位(即肌节)中的蛋白质发生突变可能与肥厚型心肌病(HCM)、限制型心肌病(RCM)和扩张型心肌病(DCM)有关。对受影响个体进行基因检测以识别致病突变已成为临床实践,这为对有疾病发展风险的亲属进行症状前检测提供了依据。这确保了对突变携带者进行充分的临床随访,而非携带者则可出院。然而,在基因检测可用于个体风险评估和预后预测之前,重要的是研究该疾病的临床疾病表现(表型)与特定疾病基因中的突变(基因型)之间是否存在关联。
我们回顾了与据报道与心肌肌钙蛋白I(cTnI;TNNI3)突变相关的表型特征有关的文献,cTnI是所有三种心肌病中公认的肌节疾病基因。
该综述结果未确定HCM或DCM中的特定基因型-表型关系,且cTnI似乎是RCM中最常见的疾病基因。
为进一步探索是否存在基因型-表型关系,需要进行长期随访研究。必须调查受影响个体中该疾病的自然史,并对健康突变携带者的疾病发展进行临床随访。需要此类信息为受影响的家庭提供循证咨询,并阐明关于特定基因型的知识是否可用于未来的风险预测模型。